CVS Group Plc (CVSG)
London Exchange · UK · prices in GBX · close of 22 Oct 2026
Key indicators
| Last close | GBX 1,299.00 |
|---|---|
| 52-week range | 1,062.00 – 1,448.00 |
| Return, 1 month / 3 months | −1.1% / −0.2% |
| Return, 1 year / 3 years | −7.5% / −12.8% |
| Trend | Uptrend |
| RSI (14) | 60 |
| Volatility (1 year) | 26.1% |
| Worst drawdown (1 year) | -21.3% |
| Average daily value traded | 389.11M GBX |
| Dividend yield | 0.7% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
CVS Group is a veterinary services company based in the United Kingdom. It owns and operates a large network of small animal veterinary practices, which trade under their own local names and provide routine care, consultations, vaccinations, surgery and dentistry for pets. Alongside the practices, the group runs supporting services including diagnostic laboratories, imaging equipment supply and pet cremation facilities, serving pet owners and veterinary professionals across the country.
On this site CVS Group Plc appears as a stock on the London Exchange (UK), code CVSG, with prices in pence sterling (GBX). Our dividend records, which start in 2019, show payments in 6 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
CVS Group Plc (CVSG) trades on the London Exchange in UK. It last closed at GBX 1,299.00 on 22 October 2026.
Its price-based Market X-Ray is 62 out of 100 (a fair price profile), ranking 1,132 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 7.5% and over the last three months it fell 0.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 61 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 3.6% | ||
| From 52-week high | -8.8% | ||
| Momentum | 50 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -0.2% | ||
| 6-month return | 6.5% | ||
| 12-month return, skipping the last month | -6.5% | ||
| Stability (higher is calmer) | 71 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 26.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -21.3% | ||
| Liquidity | 95 · Strong | Trades actively. | |
| Average daily value traded | 389.11M GBX | ||
| Zero-volume days | 0.0% | ||
| Income | 25 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.7% | ||
| Years with dividends | 5 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
- Momentum: Lagging most stocks on this exchange.
- Income: Dividend is small or irregular.
Returns
| 1 week | +4.3% |
|---|---|
| 1 month | −1.1% |
| 3 months | −0.2% |
| 6 months | +6.5% |
| 1 year | −7.5% |
| 3 years | −12.8% |
| 5 years | −46.1% |
Signals
| 50-day / 200-day average | 1,267.24 / 1,253.83 |
|---|---|
| Golden / death cross (60 days) | Golden, 45 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 35.46 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 5 Nov 2026 | GBP 0.0900 |
| 6 Nov 2025 | GBP 0.0850 |
| 31 Oct 2024 | GBP 0.0800 |
| 2 Nov 2023 | GBP 0.0750 |
| 17 Nov 2022 | GBP 0.0700 |
| 18 Nov 2021 | GBP 0.0650 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.